Stocks · News reference
STAAR Surgical Reports Q2 Preliminary Net Sales To Be Over $90M
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 16, 2026, 8:02 PM
- Checked
- Jul 16, 2026, 8:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Stifel Maintains Hold on Staar Surgical, Lowers Price Target to $28
Stifel analyst Thomas Stephan maintains Staar Surgical (NASDAQ:STAA) with a Hold and lowers the price target from $31 to $28.
Read original at benzingaUBS Maintains Sell on Staar Surgical, Lowers Price Target to $19
UBS analyst Patrick Wood maintains Staar Surgical (NASDAQ:STAA) with a Sell and lowers the price target from $20 to $19.
Read original at benzingaWedbush Maintains Outperform on Staar Surgical, Lowers Price Target to $37
Wedbush analyst Michael Piccolo maintains Staar Surgical (NASDAQ:STAA) with a Outperform and lowers the price target from $40 to $37.
Read original at benzinga